论文部分内容阅读
目的观察负荷剂量的瑞舒伐他汀与阿伐他汀治疗急性冠脉综合征(ACS)的临床效果。方法选取医院心内科治疗的ACS患者112例,随机分为瑞舒伐他汀与阿托伐他汀组各56例,观察分析2组间的临床治疗效果。结果治疗前,2组患者血清低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)水平比较差异无统计学意义(P>0.05);治疗4周后,2组患者血清LDL-C水平均有显著下降(P<0.05),HDL-C水平显著提高(P<0.05),同时瑞舒伐他汀组LDL-C值显著低于阿托伐他汀组,而HDL-C值显著高于阿托伐他汀组(P<0.05)。治疗前2组间IL-18、CRP值比较差异无统计学意义(P>0.05),治疗4周后IL-18、CRP值较治疗前均显著下降(P<0.05),且瑞舒伐他汀组LDL-C值与CRP值均显著低于阿托伐他汀组(P<0.05)。治疗24d后,瑞舒伐他汀组治疗总有效率显著高于阿托伐他汀组(P<0.05)。结论 ACS患者应用负荷剂量的瑞舒伐他汀治疗,其治疗效果显著优于阿托伐他汀,其具有更佳的调脂、抗炎功效,因此值得在临床上推广应用。
Objective To observe the clinical effect of loading dose of rosuvastatin and atorvastatin on acute coronary syndrome (ACS). Methods A total of 112 ACS patients treated with cardiology in our hospital were randomly divided into rosuvastatin group and atorvastatin group, with 56 cases in each group. The clinical effects of the two groups were observed and analyzed. Results Before treatment, there was no significant difference in serum LDL-C and HDL-C between the two groups (P> 0.05). After 4 weeks of treatment, the levels of serum LDL-C and HDL- Serum LDL-C levels were significantly decreased (P <0.05), HDL-C levels were significantly increased (P <0.05), while rosuvastatin group LDL-C was significantly lower than atorvastatin group, while HDL-C Value was significantly higher than the atorvastatin group (P <0.05). There was no significant difference of IL-18 and CRP between the two groups before treatment (P> 0.05). After 4 weeks of treatment, the levels of IL-18 and CRP decreased significantly (P <0.05), and rosuvastatin Group LDL-C and CRP values were significantly lower than the atorvastatin group (P <0.05). After treatment for 24 days, the total effective rate of rosuvastatin group was significantly higher than that of atorvastatin group (P <0.05). Conclusions The use of loading dose of rosuvastatin in patients with ACS is superior to atorvastatin in the treatment of ACS. It has better lipid-lowering and anti-inflammatory effects and is therefore worthy of clinical application.